Companies
/Healthcare
Bristol-Myers Squibb Company
$61.35
▼ $1.58 (−2.51%) today
Markets closed · 9:16am ET
Bristol-Myers Squibb (BMY) Earnings History & Trends
100%
EPS beat rate
+16.14%
Avg. EPS surprise
Consecutive EPS beats
BMY vs Market · 30-day return after each reportBMYS&P 500
BMY EPS Trend · estimate vs actualEstimateActual
BMY Revenue Trend · estimate vs actualEstimateActual
How Often Does Bristol-Myers Squibb Beat Earnings Estimates?
Bristol-Myers Squibb beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Non-GAAP EPS includes a $(0.58) per share net impact from Acquired IPRD charges ($1,558 million) and licensing income; gross margin also reflects a one-time contract termination charge. GAAP EPS of $1.05 additionally reflects $606 million of after-tax specified items, including $458 million amortization of acquired intangibles and $187 million restructuring provision. | $1.35 est. $1.23 | +9.48% | $13.1B est. $12.7B | +2.67% |
| Q2 2026 | $2.04 est. $1.60 | +27.74% | $13.0B est. $11.7B | +10.53% |
| Q1 2026 | $1.58 est. $1.42 | +11.14% | $11.5B est. $10.9B | +5.24% |
| Q4 2025 | $1.26 est. $1.20 | +4.57% | $12.5B est. $12.3B | +1.79% |
| Q3 2025 | $1.63 est. $1.52 | +7.56% | $12.2B est. $11.8B | +3.58% |
| Q2 2025 | $1.46 est. $1.10 | +32.59% | $12.3B est. $11.4B | +7.77% |
| Q1 2025 | $1.80 est. $1.50 | +19.88% | $11.2B est. $10.7B | +4.62% |
Figures from SEC filings and company reports. Not investment advice.